In the Journals

Fibrosis linked with mortality, liver-related morbidity risk in patients with NAFLD

February 6, 2020
Biopsy-confirmed fibrosis was associated with risk for mortality and liver-related morbidity in patients with NAFLD, regardless of confounding…

FDA News

Antisense oligonucleotide therapy for triglyceride reduction shows positive top-line results

January 29, 2020
Akcea Therapeutics and Ionis Pharmaceuticals announced that a phase 2 study of AKCEA-ANGPTL3-LRx for the treatment of patients with…

In the Journals

Individuals with alcohol use disorder have an increased fibrosis risk

January 27, 2020
The risk of fibrosis is highest in young adults with harmful drinking patterns and steatosis, according to data from a population-based study…

Interim analysis of metabolic modulators shows efficacy in NAFLD

January 14, 2020
Axcella released an update from the ongoing clinical study of two potential therapies for nonalcoholic fatty liver disease that showed the compounds…

NASHNET designates eighth center of excellence

January 9, 2020
NASHNET has designated the Central Virginia VA Health Care System as its eighth founding charter member and “center of excellence” in…

In the Journals

Histological noninvasive tools define distinct profiles between NAFLD, NASH

January 8, 2020
Both the fatty liver inhibition of progression algorithm and the steatosis activity and fibrosis scoring system identified distinct clinical and…

Enrollment to test NASH drug candidate complete

January 7, 2020
Akero Therapeutics announced that it has completed enrollment for a phase 2a study of AKR-001, the company’s FGF21 analog candidate for the…

In the Journals

ACG issues new guideline on hepatic, mesenteric circulation disorders

January 6, 2020
The American College of Gastroenterology released a new guideline on disorders of the mesenteric, portal, and hepatic veins and mesenteric and…

PXL065 proves safe, well-tolerated ahead of phase 2 trial for NASH

December 26, 2019
Poxel announced positive safety, tolerability and pharmacokinetic results from a phase 1b multiple ascending dose trial of PXL065, a…

Boehringer Ingelheim discontinues work on NASH therapy candidate

December 23, 2019
Boehringer Ingelheim and Pharmaxis announced that development of BI 1467335 for the treatment of nonalcoholic steatohepatitis would be discontinued…

NASH pipeline highlights from 2019

December 20, 2019
Excitement has peaked this year for potential nonalcoholic steatohepatitis therapies as many more studies have revealed positive outcomes in either…

In the Journals

Blood test differentiates between NAFLD, NASH

December 20, 2019
A novel combinations of glycans, lipids and hormonal variables can simultaneously diagnose the presence of nonalcoholic fatty liver or nonalcoholic…

Cilofexor misses primary NASH endpoint, improves liver function in combination therapy

December 17, 2019
Results from the phase 2 ATLAS study showed that neither monotherapy nor combined therapy with cilofexor reached the endpoint of significant…

Meeting News

Doptelet cost-effective, avoids transfusions for CLD-related thrombocytopenia

December 12, 2019
Treatment with Doptelet was cost-effective for the treatment of thrombocytopenia in patients with chronic liver diseases compared with other…

In the Journals

GALAD score detects early HCC with strong accuracy

December 11, 2019
The GALAD score was superior to individual serum markers in detecting hepatocellular carcinoma in patients with nonalcoholic steatohepatitis…

In the Journals

Alcohol use increases risk for clinically defined NAFLD

December 11, 2019
Alcohol use was a significant risk factor for clinically defined nonalcoholic fatty liver disease due to association with alcohol use and liver fat…

Galectin settles plans for phase 3 trial of NASH-cirrhosis therapy

December 10, 2019
Galectin Therapeutics announced plans for a phase 3 clinical trial of belapectin for patients with nonalcoholic steatohepatitis-related cirrhosis…

Meeting NewsVideo

AI tool for NAFLD could ‘make biopsies history’

December 10, 2019
LOS ANGELES — In this video exclusive, Christos S. Mantzoros, MD, PhD, professor of medicine at Harvard Medical School, chief of…

Meeting NewsVideo

VIDEO: Novel treatments show efficacy for fatty liver, cirrhosis

December 5, 2019
BOSTON — In this exclusive video from The Liver Meeting 2019, Manu Chakravarthy, MD, PhD, chief medical officer and senior vice president of…

Meeting NewsVideo

VIDEO: Patient reported outcomes define pathway for fatty liver treatment

December 5, 2019
BOSTON — In this exclusive video from The Liver Meeting 2019, Zobair M. Younossi, MD, chairman of the department of medicine at Inova Fairfax…